Moxifloxacin: A review of its in vitro activity, clinical efficacy, and adverse effects

Nathan P. Wiederhold, David J. Ritchie

Resultado de la investigación: Review articlerevisión exhaustiva

2 Citas (Scopus)

Resumen

Moxifloxacin is an 8-methoxy-fluoroquinolone antibiotic with a broad spectrum of activity. Its in vitro activity and pharmacodynamic properties make it a useful agent for the treatment of community-acquired respiratory tract infections. In clinical trials, oral moxifloxacin has shown similar efficacy to clarithromycin and high-dose amoxicillin for community-acquired pneumonia; clarithromycin and azithromycin for acute exacerbations of chronic bronchitis; cefuroxime axetil for sinusitis; and cephalexin for uncomplicated skin and skin structure infections. There are minimal published data regarding the use of moxifloxacin for nosocomial infections, infections caused by anaerobic organisms, or for treatment of any infections with the intravenous formulation. Overall, moxifloxacin is well-tolerated with a drug interaction and safety profile similar to that of other fluoroquinolones.

Idioma originalEnglish (US)
Páginas (desde-hasta)1-26
Número de páginas26
PublicaciónJournal of Infectious Disease Pharmacotherapy
Volumen6
N.º1
DOI
EstadoPublished - abr. 12 2003
Publicado de forma externa

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)

Huella

Profundice en los temas de investigación de 'Moxifloxacin: A review of its in vitro activity, clinical efficacy, and adverse effects'. En conjunto forman una huella única.

Citar esto